PTAFR and neoplasm: Moreover, platelet-activating factor (PAF), the endogenous PAFR ligand, is known to promote tumor initiation and to enhance tumor cell extravasation and metastasis formation in vivo, while this effect is inhibited by a PAF antagonist [35,50].